

Evgeny Kuleskiy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/461966/publications.pdf>

Version: 2024-02-01

29
papers

1,695
citations

430874

18
h-index

552781

26
g-index

33
all docs

33
docs citations

33
times ranked

3476
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	7
2	High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro. <i>Biomolecules</i> , 2020, 10, 1365.	4.0	22
3	Identification and Tracking of Antiviral Drug Combinations. <i>Viruses</i> , 2020, 12, 1178.	3.3	48
4	Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1. <i>Journal of Biological Chemistry</i> , 2020, 295, 4194-4211.	3.4	48
5	Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. <i>Cancers</i> , 2020, 12, 1694.	3.7	13
6	TBIO-18. ESTABLISHING A PIPELINE FOR INDIVIDUALIZED TREATMENT OPTIONS FOR PEDIATRIC BRAIN CANCER. <i>Neuro-Oncology</i> , 2020, 22, iii470-iii470.	1.2	0
7	Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma. <i>BMC Cancer</i> , 2019, 19, 628.	2.6	55
8	Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. <i>Clinical and Translational Medicine</i> , 2019, 8, 33.	4.0	20
9	Anagrelide for Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 1676-1687.	7.0	14
10	Methods for High-throughput Drug Combination Screening and Synergy Scoring. <i>Methods in Molecular Biology</i> , 2018, 1711, 351-398.	0.9	140
11	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2060-2071.	4.1	33
12	PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	116
13	Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. <i>Gynecologic Oncology</i> , 2017, 144, 621-630.	1.4	26
14	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. <i>Viruses</i> , 2017, 9, 271.	3.3	39
15	Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human Macrophages. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3203-3219.	3.8	66
16	HB-GAM (pleiotrophin) reverses inhibition of neural regeneration by the CNS extracellular matrix. <i>Scientific Reports</i> , 2016, 6, 33916.	3.3	43
17	HMGB4 is expressed by neuronal cells and affects the expression of genes involved in neural differentiation. <i>Scientific Reports</i> , 2016, 6, 32960.	3.3	14
18	Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing. <i>Journal of the Association for Laboratory Automation</i> , 2016, 21, 27-36.	2.8	22

#	ARTICLE	IF	CITATIONS
19	Antifungal Application of Nonantifungal Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1055-1062.	3.2	65
20	A personalised medicine drug sensitivity and resistance testing platform and utilisation of acoustic droplet ejection at the Institute for Molecular Medicine Finland. <i>Synergy</i> , 2014, 1, 78.	1.1	4
21	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. <i>Scientific Reports</i> , 2014, 4, 5193.	3.3	243
22	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	9.4	334
23	Transmembrane Prostatic Acid Phosphatase (TMPAP) Interacts with Snapin and Deficient Mice Develop Prostate Adenocarcinoma. <i>PLoS ONE</i> , 2013, 8, e73072.	2.5	28
24	Ligand-induced dimerization of syndecan-3 at the cell surface. <i>Advances in Bioscience and Biotechnology (Print)</i> , 2013, 04, 36-44.	0.7	1
25	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. <i>Blood</i> , 2013, 122, 482-482.	1.4	0
26	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. <i>Blood</i> , 2012, 120, 288-288.	1.4	1
27	Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. <i>Journal of Cell Biology</i> , 2011, 192, 153-169.	5.2	164
28	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. <i>Blood</i> , 2011, 118, 2487-2487.	1.4	0
29	N-syndecan deficiency impairs neural migration in brain. <i>Journal of Cell Biology</i> , 2006, 174, 569-580.	5.2	114